RETRACTION: Kuntai capsule attenuates premature ovarian failure through the PI3K/AKT/mTOR pathway (Retraction of Vol 239, art no 111885, 2019)

被引：0
|
作者：
Zhang, Han [1 ,2 ]
Qin, Fenfen [1 ,3 ]
Liu, Anlong [1 ,2 ]
Sun, Qinmei [1 ,2 ]
Wang, Qisheng [1 ,2 ]
Li, Qian [1 ,4 ]
Lu, Shengfeng [1 ,4 ]
Zhang, Dong [5 ]
Lu, Zhigang [1 ,3 ]
机构：
[1] Nanjing Univ Chinese Med, Key Lab Acupuncture & Med Res, Minist Educ, Nanjing 210023, Peoples R China
[2] Nanjing Univ Chinese Med, Clin Med Coll 1, Nanjing 210023, Peoples R China
[3] Nanjing Univ Chinese Med, Coll Pharm, Nanjing 210023, Peoples R China
[4] Nanjing Univ Chinese Med, Clin Med Coll 2, Nanjing 210023, Peoples R China
[5] Nanjing Univ, Dept Phys, Collaborat Innovat Ctr Adv Microstruct, Key Lab Modern Acoust MOE, Nanjing 210093, Peoples R China
来源：
JOURNAL OF ETHNOPHARMACOLOGY | 2022年 / 289卷
关键词：
D O I：
10.1016/j.jep.2022.115091
中图分类号：
Q94 [植物学];
学科分类号：
071001 ;
摘要：
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] RETRACTION: Long noncoding RNA OR3A4 promotes the migration and invasion of melanoma through the PI3K/AKT signaling pathway (Retraction of Vol 23, Pg 6991, 2019)
    Wu, J.
    Zhou, M. -Y.
    Yu, X. -P.
    Wu, Y.
    Xie, P. -L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (21) : 10917 - 10917
  • [22] RETRACTION: Lupeol Induces Apoptosis and Cell Cycle Arrest of Human Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway (Retraction of Vol 15, Pg NP 16, 2017)
    Liu, Yan
    Bi, Tingting
    Dai, Wei
    Wang, Gang
    Qian, Liqiang
    Shen, Genhai
    Gao, Quangen
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2017, 16 (06) : NP2 - NP2
  • [23] RETRACTION: Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells (Retraction of Vol 46, Pg 2355, 2015)
    Tian, Feng
    Ding, Ding
    Li, Dandan
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2023, 63 (03)
  • [24] The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
    Mabuchi, Seiji
    Kuroda, Hiromasa
    Takahashi, Ryoko
    Sasano, Tomoyuki
    GYNECOLOGIC ONCOLOGY, 2015, 137 (01) : 173 - 179
  • [25] The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
    Dobbin, Zachary C.
    Landen, Charles N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (04): : 8213 - 8227
  • [26] RETRACTION: GABARAP promotes bone marrow mesenchymal stem cells-based the osteoarthritis cartilage regeneration through the inhibition of PI3K/AKT/mTOR signaling pathway (Retraction of Vol 234, Pg 21014, 2019)
    Wu, Zhengyuan
    Lu, Huiping
    Yao, Jun
    Zhang, Xiaohan
    Huang, Yimei
    Ma, Shiting
    Zou, Kai
    Wei, Yan
    Yang, Zhengyi
    Li, Jia
    Zhao, Jinmin
    JOURNAL OF CELLULAR PHYSIOLOGY, 2021, 236 (05) : 4092 - 4092
  • [27] RETRACTION: Knockdown of SRPX2 inhibits the proliferation, migration, and invasion of prostate cancer cells through the PI3K/Akt/mTOR signaling pathway (Retraction of Vol 33, 10.1002/JBT.22237, 2019)
    Hong, X.
    Hong, X.
    Zhao, H.
    He, C.
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2020, 34 (12)
  • [28] RETRACTION: Promethazine inhibits neuronal apoptosis via PI3K/Akt signaling pathway in rats with cerebral infarction (Retraction of Vol 23, Pg 126, 2019)
    Pan, X. -D.
    Chen, X. -L.
    Ding, S. -F.
    Kou, D.
    Hu, H. -L.
    Li, L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (01) : 4 - 4
  • [29] RETRACTION: Aclarubicin regulates glioma cell growth and DNA damage through the SIRT1/PI3K/AKT signaling pathway (Retraction of Vol 9, Pg 28775, 2019)
    Fisher, Laura
    RSC ADVANCES, 2021, 11 (09) : 5022 - 5022
  • [30] RETRACTION: hPMSC transplantation restoring ovarian function in premature ovarian failure mice is associated with change of Th17/Tc17 and Th17/Treg cell ratios through the PI3K/Akt signal pathway (Retraction of Vol 9, art no 37, 2018)
    Yin, Na
    Wang, Yanlin
    Lu, Xueyan
    Liu, Ranran
    Zhang, Lianshuang
    Zhao, Wei
    Yuan, Wendan
    Luo, Qianqian
    Wu, Hao
    Luan, Xiying
    Zhang, Hongqin
    STEM CELL RESEARCH & THERAPY, 2022, 13 (01)
12345